Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Newron Pharmaceuticals has completed the acquisition of Hunter-Fleming, a UK-based biopharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders.
Subscribe to our email newsletter
As announced earlier, shareholders of Hunter-Fleming now hold 3.1% in Newron.
Italy based Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central nervous system and pain.